GlassScriptPhysician profile
Vivek Bansal
NPI 1831369701
$97,096.26
in general payments reported to CMS, 2019-2025
66 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $1,375 · 2021: $6,758 · 2022: $1,442 · 2023: $11K · 2024: $28K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $11K · Food and Beverage: $11K · Consulting Fee: $8,540 · Education: $86.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $32,481.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,243.75 |
| Travel and Lodging | $10,669.93 |
| Food and Beverage | $10,647.66 |
| Consulting Fee | $8,540.25 |
| Education | $86.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64,349.43 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $7,675.94 | 2021-2024 | |
| Cequr Corporation | $6,326.94 | 2023-2025 | Cequr Simplicity |
| Grt US Holding, INC. | $5,149.42 | 2021-2022 | |
| Madrigal Pharmaceuticals | $2,277.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $1,737.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,718.16 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $780.22 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.17 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $631.76 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $630.34 | 2019-2025 | Afrezza |
| Dexcom, INC. | $541.47 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $482.09 | 2019-2024 | Farxiga |
| Corcept Therapeutics | $465.09 | 2019-2025 | Korlym |
| Insulet Corporation | $393.77 | 2019-2025 | Omnipod |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $322.72 | 2019-2025 | Evenity, Prolia, Tepezza |
| Medtronic, INC. | $226.19 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Vivus LLC | $188.83 | 2019-2025 | Qsymia, Pancreaze |
| Merck Sharp & Dohme LLC | $160.10 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $154.46 | 2019-2025 | Unithroid |
| E.R. Squibb & Sons, L.L.C. | $134.56 | 2023 | Eliquis |
| Kyowa Kirin, INC. | $112.90 | 2023-2025 | Crysvita |
| Abbvie INC. | $107.87 | 2019-2022 | |
| Ibsa Pharma INC. | $107.84 | 2020-2025 | Tirosint, Licart, Tirosint |
| Novartis Pharmaceuticals Corporation | $106.73 | 2023-2025 | |
| Pfizer INC. | $83.60 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $80.03 | 2020-2025 | Strensiq |
| Lifescan, INC. | $79.39 | 2019-2021 | |
| Amarin Pharma, INC. | $73.08 | 2019-2021 | |
| Averitas Pharma INC. | $72.58 | 2023-2025 | Qutenza |
| Genzyme Corporation | $72.00 | 2020 | |
| Recordati_rare_diseases_inc. | $71.49 | 2023-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $70.48 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $60.01 | 2023-2025 | Baqsimi |
| Beta Bionics, INC. | $59.64 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Boston Scientific Corporation | $58.85 | 2023-2024 | Varithena Administration Pack |
| Eisai INC. | $52.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.50 | 2023-2024 | Cycloset |
| Rgh Enterprises LLC | $47.48 | 2023 | |
| Echosens North America, INC. | $45.36 | 2023 | Fibroscan |
| Currax Pharmaceuticals LLC | $43.11 | 2022-2025 | Contrave |
| Janssen Pharmaceuticals, INC | $41.75 | 2019-2020 | |
| Shire North American Group INC | $40.33 | 2019 | |
| Intra-Sana Laboratories | $39.97 | 2022-2023 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Sequel Med Tech, LLC | $32.07 | 2025 | Twiist |
| Horizon Therapeutics Plc | $31.21 | 2023 | Tepezza |
| Neurocrine Biosciences, INC. | $29.40 | 2024-2025 | |
| Allergan, INC. | $28.96 | 2022 | |
| Zealand Pharma US, INC. | $27.49 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $25.74 | 2021 | |
| Valeritas, INC. | $25.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.51 | 2019-2020 | |
| Companion Medical, INC. | $23.00 | 2020 | |
| Astellas Pharma US INC | $19.13 | 2023 | Veozah |
| Almatica Pharma LLC | $17.66 | 2025 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $17.63 | 2020 | |
| Tolmar, INC. | $16.61 | 2023 | |
| Ascendis Pharma Endocrinology INC | $15.80 | 2025 | Yorvipath |
| Embecta Corp. | $15.68 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Rhythm Pharmaceuticals, INC. | $15.20 | 2024 | Imcivree |
| Antares Pharma, INC. | $14.98 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.76 | 2019 | |
| Becton, Dickinson and Company | $13.45 | 2019 | |
| Althera Pharmaceuticals LLC | $12.41 | 2021 | |
| Amryt Pharma Holdings LTD | $11.79 | 2022 | |
| Clarus Therapeutics INC. | $7.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.